EXHIBIT 99.1
                             [LOGO OF VENTIV HEALTH]

Contacts:

    Investors/Corporate:                 Media:

    John R. Emery                        Noonan/Russo Communications, Inc.
    Chief Financial Officer              Lynn Blenkhorn
    (212) 768-8000                       (212) 696-4455
    investor@ventiv.com                  media@ventiv.com



                        UPDATE ON VENTIV CREDIT FACILITY

     o    Company signs non-binding letter of intent for new credit facility of
          up to $50 million
     o    Company continues to work with current lenders to amend existing
          credit facility

NEW YORK, December 28, 2001 -- Ventiv Health, Inc (Nasdaq: VTIV), a leading
provider of comprehensive marketing and sales solutions to the pharmaceutical
and life sciences industries, announced today that it has signed a non-binding
Letter of Intent with a subsidiary of a major financial institution for a new
credit facility of up to $50 million, which would be used to refinance the
Company's existing credit facility and meet the Company's ongoing working
capital needs. It is expected that this facility will be secured by the
Company's assets, and that borrowing availability under the facility will be
based on the level of the Company's U.S.-based accounts receivable. Closing of
this new credit facility is subject to a due diligence and documentation
process, which is currently underway.

In parallel, the Company continues to work with its existing lenders to amend
the Company's existing $50 million unsecured revolving credit facility, as it is
not in compliance with certain financial covenants in this facility. It is the
Company's intention to finalize and close the new credit facility or amend its
existing credit facility during the first quarter of 2002. The Company
previously announced that it intended to amend its existing credit facility by
December 31, 2001.

Until Ventiv's existing credit facility is amended or refinanced, Ventiv's
lenders have reserved all rights and remedies, including the right to declare
all amounts outstanding under the current facility immediately payable.
Accordingly, in its Form 10-Q, Ventiv classified all amounts outstanding under
the credit facility as current at September 30, 2001.

On September 30, 2001 Ventiv had cash and equivalents of $45.1 million and debt
outstanding under the credit facility of $35 million.

This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation: risks
of general business disruption, including such risks as they relate to our
reliance on computer technology; the potential for regulatory or other change in
the pharmaceutical and life sciences industries; risks relating to compliance
with governmental regulation relating to the handling and distribution of
pharmaceutical products; our risks inherent in our international operations; our
dependence on expenditures by companies in the pharmaceutical and life sciences
industries; uncertainty related to the continued growth of pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market and to operate and compete successfully in new lines of business; our
ability to maintain large client contracts or to enter into new contracts;
uncertainties related to future incentive payments and earnings under revenue
sharing arrangements; the ability of Ventiv's lenders to exercise all rights and
remedies under our $50 million unsecured revolving credit facility pending
refinancing or amendment of the facility; and, the availability of financing for
future expansion and internal growth initiatives.

                                  End of Filing